treatment of uncomplicated plasmodium falciparum malaria in myanmar a clinical decision analysis this study was undertaken to compare costeffectiveness of three drug regimes for treatment of uncomplicated falciparum malaria in myanmar the alternative regimens in this study were chloroquine cq sulphadoxinepyrimethamine sp and mefloquine mfq along with their therapeutic efficacy in myanmar the study was performed by modeling a clinical decision tree based on a hypothetical 1000 adult uncomplicated falciparum malaria cases key variables were i three drug regimes cq sp and mfq ii three categories of therapeutic efficacy of each drug adequate clinical response acr early treatment failure etf and late treatment failure ltf according to the 1996 who protocol and iii compliance with each drug in structuring the model necessary assumptions were made the cost effectiveness was measured as cost per case cured and cost per case prevented death related to the provided drug from the providers perspective according to the present price and therapeutic efficacy sp is the most cost effective drug for a case cured in all three categories of efficacy us 012 per case cured in acr us 038 per case cured in etf and us 054 per case cured in ltf for a case prevented death cq is most cost effective in all three categories us 058 per case prevented death in the acr us 214 per case prevented death in the etf and us 251 per case prevented death in the ltf the lowest cost effective regimen is mfq for both indicators of effectiveness at the present price and therapeutic efficacy a sensitivity analysis was performed for sensitive values